[HTML][HTML] Predictive factors for response to PD-1/PD-L1 checkpoint inhibition in the field of hepatocellular carcinoma: current status and challenges
Z Macek Jilkova, C Aspord, T Decaens - Cancers, 2019 - mdpi.com
Immunotherapies targeting immune checkpoints are fast-developing therapeutic
approaches adopted for several tumor types that trigger unprecedented rates of durable …
approaches adopted for several tumor types that trigger unprecedented rates of durable …
[PDF][PDF] Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
ZM Jilkova, C Aspord, T Decaens - researchgate.net
Immunotherapies targeting immune checkpoints are fast-developing therapeutic
approaches adopted for several tumor types that trigger unprecedented rates of durable …
approaches adopted for several tumor types that trigger unprecedented rates of durable …
[PDF][PDF] Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
ZM Jilkova, C Aspord, T Decaens - pdfs.semanticscholar.org
Immunotherapies targeting immune checkpoints are fast-developing therapeutic
approaches adopted for several tumor types that trigger unprecedented rates of durable …
approaches adopted for several tumor types that trigger unprecedented rates of durable …
Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges.
Z Macek Jilkova, C Aspord, T Decaens - Cancers, 2019 - search.ebscohost.com
Immunotherapies targeting immune checkpoints are fast-developing therapeutic
approaches adopted for several tumor types that trigger unprecedented rates of durable …
approaches adopted for several tumor types that trigger unprecedented rates of durable …
[HTML][HTML] Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
ZM Jilkova, C Aspord, T Decaens - Cancers, 2019 - ncbi.nlm.nih.gov
Immunotherapies targeting immune checkpoints are fast-developing therapeutic
approaches adopted for several tumor types that trigger unprecedented rates of durable …
approaches adopted for several tumor types that trigger unprecedented rates of durable …
Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges.
C Aspord, T Decaens - Cancers, 2019 - europepmc.org
Immunotherapies targeting immune checkpoints are fast-developing therapeutic
approaches adopted for several tumor types that trigger unprecedented rates of durable …
approaches adopted for several tumor types that trigger unprecedented rates of durable …
Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
ZM Jilkova, C Aspord, T Decaens - Cancers, 2019 - search.proquest.com
Immunotherapies targeting immune checkpoints are fast-developing therapeutic
approaches adopted for several tumor types that trigger unprecedented rates of durable …
approaches adopted for several tumor types that trigger unprecedented rates of durable …
Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
ZM Jilkova, C Aspord, T Decaens - Cancers, 2019 - pubmed.ncbi.nlm.nih.gov
Immunotherapies targeting immune checkpoints are fast-developing therapeutic
approaches adopted for several tumor types that trigger unprecedented rates of durable …
approaches adopted for several tumor types that trigger unprecedented rates of durable …